Thyroid Eye Disease Market Expands With Targeted Therapies and Improved Diagnosis

Thyroid Eye Disease Market Overview

Thyroid Eye Disease (TED) is an autoimmune inflammatory condition affecting the tissues surrounding the eyes and is strongly associated with thyroid disorders, particularly Graves’ disease. The condition can cause orbital inflammation, eyelid retraction, double vision, periorbital swelling, and proptosis, potentially affecting both appearance and vision. According to DelveInsight, the thyroid eye disease market is being shaped by increasing disease awareness, improved diagnosis, expanding therapeutic options, and the emergence of targeted biologic treatments. The report covers the United States, EU4 countries, the United Kingdom, and Japan, with a study period from 2020 to 2034.

The disease represents the major extrathyroidal manifestation of Graves’ disease and can substantially reduce patients’ quality of life. Its clinical presentation ranges from mild ocular discomfort and dryness to severe manifestations that can threaten vision. Because mild and moderate cases may be overlooked or confused with other orbital or inflammatory conditions, the actual patient population can be difficult to identify. This diagnostic challenge has historically contributed to underdiagnosis and delayed treatment.

Thyroid Eye Disease Epidemiology and Patient Burden

The epidemiological landscape provides important insights into the future development of the thyroid eye disease treatment market. DelveInsight estimates that the total prevalence of TED across the seven major markets was approximately 2.386 million cases in 2022, with the number projected to rise during the forecast period. The United States represented the largest share, with approximately 1.012 million prevalent cases in 2022, accounting for about 42% of the total 7MM population. Germany represented approximately 13%, while Japan accounted for around 8%.

The disease also demonstrates a notable gender distribution, with women representing approximately 80% of diagnosed prevalent cases across the 7MM. The inflammatory phase commonly lasts three to six months but can persist for considerably longer, followed by an inactive fibrotic phase. Reactivation can occur after the disease becomes inactive, further complicating long-term management.

The relationship between TED and autoimmune thyroid disorders also creates an important adjacent opportunity for companies evaluating the hashimotos disease market and broader autoimmune thyroid indications. Although TED is most strongly associated with Graves’ disease, thyroid autoimmunity and abnormal thyroid function remain important considerations during diagnosis and patient management.

Thyroid Eye Disease Diagnosis and Treatment Landscape

Diagnosing TED requires clinical assessment alongside thyroid-related laboratory testing and, when appropriate, orbital imaging. Diagnosis can be relatively straightforward in patients with bilateral proptosis and established hyperthyroidism but becomes more complicated among euthyroid or hypothyroid patients, particularly those presenting with unilateral proptosis. Testing for TSH receptor antibodies, including thyroid-stimulating immunoglobulins and thyrotropin-binding inhibitory immunoglobulins, can support diagnosis. CT and MRI may also help identify orbital abnormalities and exclude alternative causes.

Early identification is particularly important because intervention during the active inflammatory phase may improve long-term outcomes. However, mild disease can remain undiagnosed, limiting access to timely treatment. Increasing awareness among clinicians and patients is therefore expected to support diagnosis and contribute to market expansion.

The treatment landscape has evolved considerably. Before the introduction of targeted therapy, corticosteroids, immunosuppressants, orbital radiation, and off-label biologics such as rituximab and tocilizumab were commonly used for moderate-to-severe active disease. DelveInsight notes that these approaches represented a market of approximately USD 37 million across the 7MM before 2019.

Thyroid Eye Disease Market Drivers

One of the strongest growth factors is the increasing recognition of untreated and undertreated TED. The condition can produce persistent ocular symptoms, cosmetic changes, functional impairment, and, in severe cases, sight-threatening complications. As awareness improves, more patients are expected to undergo appropriate evaluation and enter treatment pathways.

The approval of TEPEZZA (teprotumumab) in the United States significantly changed the therapeutic landscape. DelveInsight identifies TEPEZZA as the only FDA-approved therapy specifically indicated for TED in the report. The treatment targets insulin-like growth factor-1 receptor (IGF-1R), a pathway implicated in the disease process. Clinical benefits include reductions in proptosis and diplopia as well as improvements in disease activity and quality of life.

This targeted approach has helped establish biologics as an important component of the evolving us thyroid disorder market, while also encouraging pharmaceutical companies to investigate alternative mechanisms, administration routes, and treatment strategies.

Another major driver is the unmet need among patients who require more convenient, effective, or durable treatment. Only a portion of patients with TED develop acute moderate-to-severe disease requiring drug therapy. DelveInsight estimates that approximately 20% of cases are treated for acute disease, suggesting substantial potential for market expansion as diagnosis improves and safer and more effective therapies become available.

Thyroid Eye Disease Market Barriers

Despite substantial commercial potential, several challenges may restrict market growth. The heterogeneous presentation of TED makes diagnosis difficult, particularly in patients with mild, unilateral, euthyroid, or atypical disease. Delayed diagnosis can prevent patients from receiving treatment during the active inflammatory stage when therapeutic intervention may be most beneficial.

Treatment-related safety concerns and administration requirements can also influence adoption. Conventional corticosteroid therapy is associated with significant adverse effects, while intravenous biologic treatment can require repeated healthcare visits. These limitations create opportunities for alternative delivery methods but can also contribute to treatment discontinuation or reluctance among patients and physicians.

The cost of advanced biologic therapies and differences in reimbursement across countries represent additional challenges. Access to specialized ophthalmology and endocrinology services also varies geographically, potentially creating disparities in diagnosis and treatment.

For patients primarily concerned with proptosis and visible ocular changes, the unmet need extends beyond conventional exophthalmos treatment market approaches. Orbital decompression and reconstructive procedures may be considered in selected patients, but surgery can involve risks and may not address active inflammation. Consequently, pharmaceutical interventions capable of simultaneously reducing disease activity and ocular manifestations remain commercially attractive.

Emerging Therapies and Competitive Landscape

The TED pipeline is increasingly characterized by targeted therapies directed at immune pathways and disease mechanisms. DelveInsight identifies several promising candidates, including batoclimab, VRDN-001, and COSENTYX (secukinumab).

Batoclimab, developed by Immunovant, is a fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). The therapy is designed to reduce pathogenic IgG antibodies and has been investigated as a potentially self-administered subcutaneous treatment. Its development illustrates the industry's focus on mechanisms beyond conventional immunosuppression and on delivery approaches that could improve patient convenience.

Viridian Therapeutics’ VRDN-001, or veligrotug, is another important pipeline candidate targeting IGF-1R. In May 2025, Viridian announced that the FDA granted Breakthrough Therapy Designation to veligrotug for TED, highlighting the potential importance of this candidate in the evolving treatment landscape.

Novartis’ cosentyx thyroid eye disease development represents another area of interest, particularly because secukinumab targets inflammatory pathways distinct from IGF-1R and FcRn approaches. The emergence of therapies with different mechanisms could intensify competition and potentially provide physicians with a broader range of options for patients with different disease characteristics.

Future Outlook for Thyroid Eye Disease Treatment

The future of TED management is expected to increasingly emphasize precision treatment, earlier diagnosis, and therapies that provide durable improvements in ocular outcomes. The shift from nonspecific immunosuppression toward targeted biological treatments could substantially reshape treatment algorithms over the coming years.

According to DelveInsight, the United States held the largest TED market in 2022, valued at approximately USD 1.98 billion, and this market is expected to increase through 2034. The report anticipates that TEPEZZA will remain an important component of the US treatment landscape, while emerging therapies such as batoclimab and other pipeline candidates may introduce additional competition.

At the same time, growing disease awareness could improve identification of patients who previously remained undiagnosed. Better understanding of disease mechanisms, advances in biomarkers, and greater collaboration between endocrinologists, ophthalmologists, and other specialists may further support individualized treatment decisions.

Conclusion

The TED landscape is moving toward more targeted and patient-focused treatment strategies. Rising awareness, a substantial diagnosed and undiagnosed patient population, and advances in biologic therapies are creating meaningful opportunities for innovation. Continued clinical development and improved diagnosis could broaden access to effective interventions while addressing persistent unmet needs. As competition increases and therapeutic approaches diversify, the market is positioned for continued evolution through 2034, with treatment innovation remaining central to improving outcomes for patients affected by this complex autoimmune eye disorder.

Latest Reports by DelveInsight:

uk healthcare report, varicose vein market, antibody drug conjugate market, bone grafts and substitutes market, chemotherapy induced anemia market, hypoventilation market, paget's disease market, stem cell market, vascular grafts market, celiac disease market, dental implants and prosthesis market, diabetic retinopathy market, dilators market, eisenmenger complex market, endoscopic ultrasound market, erectile dysfunction market, exophthalmos market, mrna based vaccines and therapeutics market, spinal cord stimulators market, von willebrand disease market, aesthetic implants market, biliary tumor market, catheter stabilization devices market, compartment syndrome market, donohue syndrome market, fibrocystic breast condition market, hearing implants market

About DelveInsight 

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. 

Media Contact 

Company Name: DelveInsight Business Research LLP

Contact Person: Abhishek kumar

Email: abhishek@delveinsight.com

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com